HARROW, INC. — Director's Dealing 2018

Jan 5, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Imprimis Pharmaceuticals, Inc. (IMMY)
CIK: 0001360214
Period of Report: 2018-01-02

Reporting Person: SAHAREK JOHN P. (Chief Commercial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-01-02	Option - Right to Buy	$1.73	A	50000	Acquired	2028-01-02	Common Stock (50000)	Direct

Footnotes

F1: Represents stock options granted under the Issuer's 2017 Stock Incentive and Awards Plan. The stock options vest in equal quarterly installments over a three year period.